Peptide therapy TikTok claims: separating hype from human data

What did @seth.3.0 actually say?

The creator compared two growth hormone-releasing peptides, calling one "tesmaralan" and the other "sromoralan" — almost certainly meaning tesamorelin and sermorelin. The core claim is that tesamorelin "binds to the GHRH receptors in the pituitary gland to release more growth hormone" and is "more potent than sermorelin," which in turn makes it better for "fat loss purposes," specifically "residual body fat and belly fat."

That's a narrow but testable claim. The mispronunciations throughout the video don't inspire confidence, but the underlying comparison is worth examining because it touches on real pharmacology with an actual clinical evidence base.

Does the science back this up?

Partially, yes. Tesamorelin does have FDA-approved data specifically for visceral fat reduction, which gives it a leg up over sermorelin in that department. But framing sermorelin as simply the weaker alternative oversimplifies a more complicated picture.

Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH). It received FDA approval in 2010 under the brand name Egrifta specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The pivotal trials (Falutz et al., 2010, New England Journal of Medicine) showed statistically significant reductions in visceral adipose tissue compared to placebo. That is real, peer-reviewed evidence for visceral fat reduction in a specific population.

Sermorelin is also a GHRH analog, but it's a truncated version containing only the first 29 amino acids of endogenous GHRH, compared to tesamorelin's full 44-amino-acid sequence with a trans-3-hexenoic acid modification. Studies on sermorelin's fat-loss effects are much thinner by comparison, and none have produced FDA-approval-level evidence for visceral fat reduction specifically.

What did they get wrong (or right)?

The mechanism description is roughly correct but missing important nuance. Both peptides stimulate pituitary GHRH receptors. The creator is right that tesamorelin is more potent in a clinical sense, but the reason matters: it's not simply "more potent" in a vague way. Its structural modification makes it more resistant to enzymatic degradation, giving it a longer half-life and more sustained receptor activity.

The claim that tesamorelin helps reduce "residual body fat and belly fat" is where things get slippery. The FDA-approved evidence is for visceral adipose tissue in people with HIV-associated lipodystrophy. Extrapolating this to general fat loss in healthy adults for body composition "optimization" is a significant leap that the available evidence does not cleanly support. The creator does not make that distinction, which matters a lot for people watching this as general fitness advice.

• The mispronunciations of both drug names throughout the video suggest a limited familiarity with the clinical literature.
• No mention of the FDA approval status of tesamorelin or the off-label nature of its use in non-HIV populations.
• Sermorelin's comparative weakness on fat-loss evidence is real, but the creator doesn't explain why.

What should you actually know?

If you're considering either peptide, the regulatory and safety context is not optional background information. Tesamorelin is an FDA-approved drug with specific labeling. Sermorelin is no longer FDA-approved as a standalone drug in the US (it was withdrawn from the commercial market in 2008) but is available through compounding pharmacies under specific conditions.

Compounded versions of either peptide are not FDA-approved and carry different quality and purity assurances than approved medications. This is not a technicality. The FDA has issued warning letters to compounders related to peptide products, and the safety and efficacy profile of compounded versions cannot be assumed equivalent to studied formulations.

For fat loss specifically, the evidence for tesamorelin is strongest in a population with clinically defined lipodystrophy. Studies in healthy adults or general obesity populations are limited. A 2014 study by Stanley et al. in the Journal of Clinical Endocrinology and Metabolism did show some visceral fat reduction in HIV-negative obese adults, which is encouraging but far from a green light for broad use. Anyone considering these agents should be doing so under physician supervision with baseline IGF-1 monitoring and a clear clinical rationale, not because a TikTok video ranked one over the other.